In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent
- 1 June 1991
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 62 (5) , 567-578
- https://doi.org/10.1016/0049-3848(91)90029-v
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Epinephrine potentiation of in viw stimuli reverses aspirin inhibition of platelet thrombos formation in stenosed canine coronary arteriesThrombosis Research, 1988
- Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactionsBiochemical Pharmacology, 1987
- Platelet-inhibitor drugs' role in coronary artery diseaseProgress in Cardiovascular Diseases, 1987
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectinBlood, 1985
- Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the moleculeNature, 1984
- Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris.Circulation, 1981
- Present concepts on the mechanisms of platelet aggregationBiochemical Pharmacology, 1981
- Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial InfarctionNew England Journal of Medicine, 1980
- Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like DrugsNature New Biology, 1971